The 9th ISCC
December 2-3, 2004
Keidanren Hall
December 2, 2004 (Thursday)
13:00 - 13:10
Haruo Sugano (Cancer Chemotherapy Center, Tokyo)
Welcome and Introduction
Kinase Inhibition (Part I)
Chairpersons: Edward A. Sausville (Univ..Maryland, USA)
Ryuzo
Ueda (Nagoya City Univ., Nagoya)
13:10 - 13:40
Yoshimasa Uehara (National Institute of Infectious Diseases)
Targeting kinase in the discovery of anticancer drugs
13:40 - 14:10
Edward A. Sausville (Univ. Maryland, USA)
Adaphostin : A new tyrphostin for cancer treatment
14:10 - 14:30
Yoshinori Ito (Cancer Chemotherapy Center, Tokyo)
Lapatinib (GW572016), dual inhibitor of ErbB1 and ErbB2 receptor tyrosine kinases
14:30 - 14:50
Takayasu Kurata (Kinki Univ. Osaka)
EGFR-targeted therapy: EKB 569
14:50 - 15:10
Coffee Break
Kinase Inhibition (Part II)
Chairpersons: Robert H. Shoemaker (NCI-Frederick, USA)
Saburo
Sone (Univ. Tokushima, Tokushima)
15:10 - 15:30
Atsushi Ohtsu (National Cancer Center Hospital East, Kashiwa)
EGFR targeted therapy: EMD72000
15:30 - 16:00
Jaap Verweij (Erasmus Univ. Medical Center, Netherlands)
Do we need multitargeted agents or selected agents?
16:00 - 16:20
Discussion
Drug Resistance
Chairpersons: Jaap Verweij (Erasmus University Medical
Center, Netherlands)
Yoshiro Niitsu (Sapporo Medical Univ., Sapporo)
16:20 - 16:50
Takashi Tsuruo (Univ. Tokyo, Toyo) and Toshiaki Saeki (National Shikoku Cancer Center, Matsuyama)
MS-209 as a potentiating drug for CAF-therapy against breast cancer
16:50 - 17:20
Stanley B. Kaye (The Royal Marsden Hospital, U.K.)
The role of novel agents in reversing drug resistance
17:20 - 17:30
Discussion
17:30 - 18:30
Mixer
December 3, 2004 (Friday)
Angiogenesis and Metastasis
Chairpersons: Bruce A. Chabner (MGH Cancer Center, USA)
Nagahiro
Saijo (National Cancer Center Hospital, Tokyo)
10:00 - 10:30
Michihiko Kuwano (Kurume Univ, Kurume)
Targeting angiogenesis as a inflammatory response in tumor growth, invasion and metastasis
10:30 - 11:00
Jean Pierre Armand (Institut Gustave-Roussy, France)
The antiangiogenic competition in renal cell cancer
11:00 - 11:20
Coffee Break
11:20 - 11:50
Robert D. Mass (Director, Clinical Oncology, Genentech, USA)
Targeting VEGF in human cancer: an update on avastin
11:50 - 12:20
Robert H. Shoemaker (NCI-Frederick, USA)
Targeting β-catenin signaling for anti-metastatic therapeutics
12:20 - 12:30
Discussion
12:30 - 13:30
Lunch Break
New Drugs under Clinical Consideration
Chairpersons: Jean-Pierre Armand (Institut Gustave Roussy,
France)
Masahiro Fukuoka (Kinki Univ., Osaka)
13:30 - 13:50
Kiyohiko Hatake (Cancer Chemotherapy Center, Tokyo)
PS341
13:50 - 14:10
Yukito Ichinose (National Kyushu Cancer Center, Fukuoka)
Chemotherapy trials using (S-1) DPD-inhibitory fluoropyrimidine for advanced non-small cell lung cancer patients in Japan
14:10 - 14:30
Yasuhide Yamada (National Cancer Center Hospital, Tokyo)
Phase I and pharmacokinetic/pharmacogenomic study of E7070
14:30 - 15:00
Tomomitsu Hotta (Tokai Univ, Isehara)
Erythropoietin in cancer chemotherapy
15:00 - 15:10
Discussion
15:10 - 15:30
Coffee Break
Molecular Target Therapy of Cancer: Future Prospective
Chairpersons: Stanley B. Kaye (the Royal Marsden Hospital,
U.K.)
Yutaka Ariyoshi (Aichi Hosp., Nagoya)
15:30 - 16:00
Masaaki Matsuura (Cancer Institute, Tokyo)
Pharmacogenomics studies in cancer patients for genomic prediction of adverse effect
16:00 - 16:30
Bruce A. Chabner (MGH Cancer Center, USA)
Targeted Drug Development: Impact of Selective Factors
16:30 - 17:00
Enrico Mihich (Grace Cancer Drug Center, Roswell Park Cancer Institute, USA)
Development of new anticancer treatment
17:00 - 17:20
Discussion
17:20 - 17:30
Takashi Tsuruo (Univ. Tokyo, Tokyo)
Closing Remark
